The slow-moving fight over marijuana's federal status just reached its final stage, and while it isn't over, the outline of the endgame is now visible.
Where things stand
The DEA's formal hearing on moving marijuana from Schedule I to Schedule III wrapped up on July 15, 2026, after 11 days of testimony. The chief administrative law judge set August 17 as the deadline for post-hearing briefs, the parties' written closing arguments. With those filed, the record is essentially closed.
There's an important wrinkle many people miss: part of the rescheduling has already happened. A DEA order moved FDA-approved marijuana drug products and marijuana under a state medical license to Schedule III, effective April 28, 2026. But all other marijuana, including adult-use and medical outside a licensed state program, remains Schedule I while the broader question is decided.
What happens next
After the briefs, the administrative law judge issues a recommendation to the DEA Administrator, who holds the final decision authority. Realistically, a final answer on whether and how the rest of cannabis gets rescheduled is expected by late 2026 or early 2027.
The New York angle
For New York's licensed operators, the stakes come down to two numbers: 280E and their tax bill. Under IRS code Section 280E, businesses that "traffic" in Schedule I or II substances can't deduct normal expenses like rent and payroll, which pushes effective tax rates far above other retailers. A full move to Schedule III would lift that burden, freeing up cash for shops already squeezed by high costs and falling prices.
Rescheduling would not legalize cannabis federally or fix banking on its own, but for an operator watching every dollar, escaping 280E would be one of the most meaningful changes in years. New York's adult-use businesses are still Schedule I today, so for now, the watching and waiting continues. Cannabis products are for adults 21+.